Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide

Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture. Because market exclusivity for brand teriparatide expired in August 2019 in the US, we sought to understand th...

全面介紹

Na minha lista:
書目詳細資料
發表在:JBMR Plus
Main Authors: Mori, Takahiro, Crandall, Carolyn J, Ganz, David A
格式: Artigo
語言:Inglês
出版: John Wiley & Sons, Inc. 2019
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6874180/
https://ncbi.nlm.nih.gov/pubmed/31768491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbm4.10233
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍